Over the past 5 years, living with the constant threat of COVID-19 has been a daily struggle due to my exceptionally high risk for severe long-term consequences from an infection. The anxiety of encountering the virus and the potential for debilitating health issues or exacerbating existing conditions is something I face constantly. For individuals like me, timely access to updated COVID-19 vaccinations is not just a preference; it's necessary to maintain our health and peace of mind. As a [health policymaker/public health official responsible for vaccine distribution and approval], your decisions directly impact our lives.

COVID-19 continues to evolve, with new variants that challenge our current vaccination strategy

Over the past year, the constant threat of COVID-19 has posed significant challenges for me, given my exceptionally high risk of severe long-term consequences from infection. The ever-present anxiety surrounding the possibility of encountering the virus has become a daily burden. For individuals like me, timely access to updated COVID-19 vaccinations is not merely a preference but a fundamental necessity to safeguard our health and nurture our peace of mind.

As COVID-19 evolves, new variants consistently challenge our current vaccination strategies. Since the initial trials in 2020, our understanding of these vaccines has advanced remarkably, yielding a wealth of data on their safety and efficacy. The innovative technology behind these vaccines, such as mRNA, allows for swift adaptations to combat emerging strains. However, the requirement for updated vaccines to undergo extensive and lengthy clinical trials, similar to those for new drugs, unfortunately delays our access to critical protection.

We can adopt expedited approval processes, which have been effectively utilized for annual flu vaccines based on years of accumulated data, to fast-track the release of updated COVID-19 vaccines. By leveraging ongoing, real-world clinical evidence, we can ensure rigorous safety monitoring while promptly protecting those at high risk.

We mustn't leave the most vulnerable members of our society defenseless against the evolving threat of new variants. Now, more than ever, we must act with urgency and compassion to safeguard their health and well-being.

The science has significantly evolved since the initial trials in 2020, and we now have a wealth of data on the safety and efficacy of these vaccines. The technology used in creating these vaccines, like mRNA, offers the flexibility to update them swiftly to combat new strains. Requiring these updated vaccines to undergo extensive, lengthy clinical trials, similar to new drugs, delays our ability to access them and may put lives at risk.